Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][4][6]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses and differentiation from competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations and Stock Impact - The company previously claimed strong performance in its North American fiber cement segment, but it is alleged that sales were inflated due to inventory loading by channel partners, rather than genuine customer demand [5]. - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, leading to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6]. Group 4: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [7].

Core Insights - Bleichmar Fonti & Auld LLP is investigating Jefferies Financial Group Inc. and Point Bonita Capital for potential violations of federal securities laws following an SEC probe [1][5][9] Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital is its trade finance arm [3] - Both firms were closely associated with First Brands Group, LLC, an auto parts supplier that filed for bankruptcy in September 2025 [3] Financial Exposure - Jefferies and Point Bonita reported approximately $715 million in exposure to First Brands' receivables, which constitutes about 25% of Point Bonita's trade finance portfolio [4] - Following the announcement of this exposure, Jefferies' stock price dropped by $4.66, or approximately 8%, from $59.10 to $54.44 per share [4] SEC Investigation Details - The SEC is investigating whether Jefferies provided adequate information to investors regarding their exposure to the auto business, which had $12 billion in debt at the time of bankruptcy [5] - The SEC is also examining internal controls and potential conflicts of interest within Jefferies and Point Bonita [5] Legal Implications - Bleichmar Fonti & Auld LLP is assessing whether Jefferies and/or Point Bonita made materially false and misleading statements to investors concerning their significant exposure to First Brands [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Stride securities between October 22, 2024, and October 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Stride made misleading statements about its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits, which led to damages for investors when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of James Hardie Industries plc to secure legal counsel before the December 23, 2025 deadline for a securities class action lawsuit related to misleading statements about the company's performance during a specific period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A lawsuit has been filed claiming that James Hardie misled investors regarding the strength of its North America Fiber Cement segment, falsely asserting that demand was strong while distributors were actually destocking inventory [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Perrigo Company plc to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the securities class action is from February 27, 2023, to November 4, 2025, inclusive [2]. - Investors who purchased Perrigo securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by January 16, 2026 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including issues related to underinvestment, necessary capital expenditures, and manufacturing deficiencies [6]. - As a result of these misstatements, Perrigo's financial results were overstated, leading to investor damages when the true information became public [6].

Core Viewpoint - Rosen Law Firm is urging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action related to misleading statements made during the Class Period from May 16, 2024, to August 5, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 8, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][7]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].

Core Viewpoint - The Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Summary by Sections Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [3]. Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom downplayed the severity of these issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - Rosen Law Firm is urging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased or sold Cepton common stock during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 8, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][6]. - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].